Bristol-Myers Squibb faces revenue declines but offers long-term potential via growth drugs. Read what BMY stock has to offer ...

Discover why Bristol-Myers Squibb's undervalued stock, strong cash flow, and 5% dividend yield make it an attractive buy ...

Bristol Myers Squibb (BMY) closed at $47.51 in the latest trading session, marking a +2.64% move from the prior day.

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) has received an average rating of “Hold” from the twenty-two brokerages that are presently covering the firm, MarketBeat reports. Two ...

Investors in Bristol-Myers Squibb Company BMY need to pay close attention to the stock based on moves in the options market lately. That is because the July 18, 2025 $25 Call had some of the highest ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Ashish Patil stands at the forefront of this evolution, transforming logistics through innovation, decision intelligence, and ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...